AstraZeneca has agreed to take a $2-billion equity stake in Summit Therapeutics, a Miami-based bio/pharmaceutical company, and the companies have formed a clinical collaboration to evaluate Summit’s ...

Novo has entered into a license agreement with Hengrui Pharma, a Shanghai-based bio/pharmaceutical company, for HRS-1596, a Phase I-ready glucagon-like peptide-1 receptor (GLP-1R) and gastric ...

The latest from CDMOs, CMOs, and suppliers featuring SK pharmteco, Esteve CDMO, Vetter, Sharp Services, Piramal Pharma Solutions, SPI Pharma, Colorcon, Lonza, and Bespak. Chemicals/Chemical API ...

Sanofi has expanded its antibody collaboration with Regeneron Pharmaceuticals, a Tarrytown, New York-based bio/pharmaceutical company, to add four new drug candidates in an $8-billion deal ($1 billion ...

The White House is moving to identify new and unused domestic, US-based, and near-shore production capacity to meet a goal of localizing manufacturing of essential medicines.

Roche’s Genentech has broken ground on a $750-million, 211,000-square-foot expansion of its manufacturing facility in Hillsboro, Oregon, to add device fill–finish capabilities, including the ...

What is the state-of-the state for biomanufacturing (drug substance) in terms of industry capacity utilization, in-sourced/outsourced activity, and technology drivers? Is capacity in line with demand ...

How are small-molecules faring in 2026? To answer that question, DCAT Value Chain Insights examined where the small-molecules drugs among the 11 drugs identified by Clarivate, a business intelligence ...

Novo’s CEO Mike Doustdar laid out a strategic growth plan for the company, which included a plan to launch more than five ...

A recent analysis by Gartner projects low uptake of AI for supply-chain planning decisions by 2030, but AI does factor into ...